Janssen Approved for Expanded Indication of ZYTIGA (JNJ)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
FDA Said to Approve Expanded Indication for Janssen's (JNJ) Zytiga
December 10, 2012 1:18 PM ESTJohnson & Johnson (NYSE: JNJ) Janssen Bioscience is said to have gotten an expanded indicating for its late-stage prostate cancer drug, Zytiga. Headlines come from Bloomberg this afternoon.
Johnson & Johnson shares are positive on the session Monday.... More
